Medical Dialysis News
-
Ovivo’s Women for Water presents: Astrid Kloosterman
Career Progression Through Adaptability and Education Choosing a career path can be a daunting task, and it’s not uncommon for people to change their minds before discovering their true aspiration. However, staying determined to find your passion is essential to finding the career you will love. Astrid is a great example of how a person can find their true calling and choose to pursue ...
-
What is the manufacturing process flow of medical sterilization packaging bags?
The manufacturing process of medical sterilization packaging bag includes the upper film and the base paper, which is characterized in that a circle of water-based adhesive is coated on the four frames of the back of the base paper, and the back paper and the upper film are heated at the position where the water-based adhesive is coated on the back of the paper to form a medical sterilization ...
-
Common problems and countermeasures in the production of medical sterilized paper plastic packaging bags
The medical sterilization paper plastic packaging bag is a disposable medical sterilization packaging material, which has the advantages of good air permeability, good penetration of sterilization medium, high bacteria resistance after sterilization, convenient chemical monitoring during sterilization, simple package sealing, good perspective, long safety period after sterilization, easy opening, ...
-
Stanford Surgeon Venita Chandra Joins Alucent Biomedical Scientific Advisory Board as Company Enters Arteriovenous Fistula Market
Alucent Biomedical, a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D., will join the company’s scientific advisory board. Dr. Chandra is board certified in both general and vascular surgery. She is a clinical associate professor of surgery in the Division of Vascular Surgery at Stanford University ...
-
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- Alnylam ...
-
Quanta Announces CEO Transition
Quanta Dialysis Technologies Inc (“Quanta or “The Company”), a medical technology company committed to making kidney care more accessible with its SC+ hemodialysis system, announced today that CEO John E. Milad will leave the company effective July 15, 2022. The company has begun the search for a new CEO. Upon Milad’s departure and until the appointment of a new CEO, ...
-
Bodyport Appoints John Lipman as Chief Executive Officer
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, today announced the appointment of medtech industry veteran, John Lipman, as Chief Executive Officer. Bodyport co-founder, Corey Centen, will continue as President and also serve as Chief Technology Officer (CTO) of the company. Lipman’s appointment comes as Bodyport prepares for ...
-
Major Biomedical Catalyst grant win
£1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of ...
-
Medical Indicators, Inc. Attending HCANJ Assisted Living Conference
Medical Indicators is excited to participate in the Health Care Association of New Jersey’s Assisted Living Conference, on May 17, 2022. The event provides educational programming that is designed to advance the assisted living profession and promote excellence in standards of care. Educational sessions will feature presentations from local, state, and national leaders in the healthcare ...
-
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients First launches in Europe expected in H2 2022 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Commission has granted marketing authorization to Kapruvia® (difelikefalin) for the ...
-
Second grant win to research Peritoneal Dialysis indication
Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard technology. Globally there are 3.5 million patients who are ...
-
Home Dialysis Patients Face Postcode Lottery of Care, New Report Finds
QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the Gap report finds that failure to offer such treatment ...
-
Tablo Hemodialysis System Cartridge Receives FDA 510(k) Clearance Enabling Production in North America
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a new sterilization method of the cartridge utilized in its Tablo® Hemodialysis System, enabling full production in North America. The Tablo cartridge is a ...
-
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus (CKD-aP) in hemodialysis patients European Commission decision for EU Marketing Authorization is expected in Q2 2022 Kapruvia® is approved in the U.S. under the trade name KORSUVA™ ...
-
CloudCath Announces $12 Million Series A Financing for Technology Enabling Remote, Real-Time Complication Monitoring for At-Home Dialysis
A July 2019 White House executive order on kidney care (the Advancing American Kidney Health Initiative) proposed that 80% of new patients with end-stage renal disease (ESRD) be treated with either kidney transplantation or home dialysis by 2025, a significant increase from current rates, which are below 20%. “End-stage renal disease, one of the costliest chronic diseases in the U.S., is ...
By CloudCath
-
ExThera Medical & Fresenius Medical Care Sign Distribution Agreement for Seraph 100 Blood Purification Device in Mexico
Seraph 100 used for Blood Purification and Pathogen Reduction in Sepsis and COVID-19 Treatments MARTINEZ, Calif. – ExThera Medical and Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, announced the expanded distribution of ExThera’s Seraph® 100 Microbind® Affinity Blood Filter in Mexico. In 2021, ExThera ...
-
Vascular experts discuss aXess in dialysis patients
Vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD, PhD, professor emeritus of vascular surgery at the University Medical Center Utrecht in The Netherlands, provided insights on the progress of the aXess trial in an interview with Healio Nephrology. For more on Xeltis’ aXess, the first restorative synthetic ...
By XELTIS BV
-
Cara Therapeutics Announces Difelikefalin (KORSUVA) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd., and its sublicensee Kissei Pharmaceutical Co., Ltd., confirmed the primary endpoint was achieved in a Japanese Phase 3 clinical study ...
-
Outset Medical Named to Fast Company’s First-Ever List of the Next Big Things in Tech
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it has been named to Fast Company’s inaugural Next Big Things in Tech list, honoring the technology breakthroughs that promise to shape the future of their industries — from healthcare to ...
-
Potrero Medical Announces Launch of New Furosemide Stress Test App
Potrero Medical, innovator of the Accuryn Monitoring System, announced the launch of its newest software App for the Accuryn™ Monitor and AccuTab™. The Accuryn Monitoring System includes a revolutionary sensor-integrated foley catheter that provides real-time, actionable information to healthcare providers, enabling them to take important, earlier steps to prevent disease state ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you